Literature DB >> 23160610

[The results of the European randomized study of screening for prostate cancer (ERSPC) 2012: confirmation or disappointment?].

C Schaefer, L Weissbach.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 23160610     DOI： 10.1007/s00120-012-3058-4

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  23 in total

1.  PSA is dead, long live PSA.

Authors:  Andrew J Vickers; Hans Lilja
Journal:  Eur Urol       Date:  2011-12-03       Impact factor: 20.096

2.  Prostate-cancer screening--what the U.S. Preventive Services Task Force left out.

Authors:  Allan S Brett; Richard J Ablin
Journal:  N Engl J Med       Date:  2011-10-26       Impact factor: 91.245

3.  Can preoperative PSA doubling time and PSA velocity predict outcomes following radical prostatectomy?

Authors:  Robert L Grubb; Gerald L Andriole
Journal:  Nat Clin Pract Urol       Date:  2006-06

4.  [Parameters to improve the specificity of the prostate-specific antigen. Early detection of prostate cancer].

Authors:  C Börgermann; S Kliner; A Swoboda; H-J Luboldt; H Rübben
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

5.  EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease.

Authors:  Axel Heidenreich; Joaquim Bellmunt; Michel Bolla; Steven Joniau; Malcolm Mason; Vsevolod Matveev; Nicolas Mottet; Hans-Peter Schmid; Theo van der Kwast; Thomas Wiegel; Filliberto Zattoni
Journal:  Eur Urol       Date:  2010-10-28       Impact factor: 20.096

6.  Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States.

Authors:  Michael W Drazer; Dezheng Huo; Mara A Schonberg; Aria Razmaria; Scott E Eggener
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

7.  Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.

Authors:  Stacy Loeb; Robert B Nadler; Kimberly A Roehl; Jo Ann V Antenor; William J Catalona
Journal:  J Urol       Date:  2007-05       Impact factor: 7.450

8.  Mortality results from a randomized prostate-cancer screening trial.

Authors:  Gerald L Andriole; E David Crawford; Robert L Grubb; Saundra S Buys; David Chia; Timothy R Church; Mona N Fouad; Edward P Gelmann; Paul A Kvale; Douglas J Reding; Joel L Weissfeld; Lance A Yokochi; Barbara O'Brien; Jonathan D Clapp; Joshua M Rathmell; Thomas L Riley; Richard B Hayes; Barnett S Kramer; Grant Izmirlian; Anthony B Miller; Paul F Pinsky; Philip C Prorok; John K Gohagan; Christine D Berg
Journal:  N Engl J Med       Date:  2009-03-18       Impact factor: 91.245

9.  Quantifying the role of PSA screening in the US prostate cancer mortality decline.

Authors:  Ruth Etzioni; Alex Tsodikov; Angela Mariotto; Aniko Szabo; Seth Falcon; Jake Wegelin; Dante DiTommaso; Kent Karnofski; Roman Gulati; David F Penson; Eric Feuer
Journal:  Cancer Causes Control       Date:  2007-11-20       Impact factor: 2.506

10.  Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.

Authors:  Pim J van Leeuwen; David Connolly; Anna Gavin; Monique J Roobol; Amanda Black; Chris H Bangma; Fritz H Schröder
Journal:  Eur J Cancer       Date:  2009-10-03       Impact factor: 9.162
View more
  1 in total

1.  [PSA screening 2013: background and perspectives].

Authors:  F Recker; D Seiler; B Seifert; M Randazzo; M Kwiatkowski
Journal:  Urologe A       Date:  2014-06       Impact factor: 0.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.